Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PC-SPES research

This article was originally published in The Tan Sheet

Executive Summary

Herbal mixture "significantly suppressed cell proliferation in colon cancer cell lines" after 72 hours of exposure, Sergio Huerta, UCLA, et al., report in September Cancer Research. In an in vitro study, 11 female mice were given 250 mg/kg/day PC-SPES (Botanic Lab) five times a week for 10 weeks, while 10 mice in placebo group were given .2 mL "vehicle solution." Researchers also report results of in vivo study demonstrating oral PC-SPES-treated mice saw a "significant decrease in polyp number in the medial and distal segments of the small intestines." Huerta et al. conclude the supplement has "potent anticancer effects and results in both cell cycle arrest and apoptosis." UCLA is working with PC-SPES inventor to guarantee future research on herbal blend, which has been plagued by Rx contamination problems (1"The Tan Sheet" Aug. 5, 2002, In Brief)...

Related Content

Herbal-To-Rx Switch? Zyflamend To Undergo Study For Cancer Prevention
Future PC-SPES research





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts